GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
1.3k

the appetite question that gets asked weekly, answered properly

Question Receipts ×5 Long Haul ×3

the appetite question that gets asked weekly, answered properly. Change my mind, genuinely — I have no stake in being right about this.

The GIP question, which is the most interesting unsettled thing in this field.

Dual agonism at GIP and GLP-1 receptors produces clinical results that are robust and well replicated. What is not settled is the mechanism by which the GIP arm contributes — there is a genuine scientific argument about agonism versus antagonism at that receptor, with reasonable people and real data on both sides.

It is worth sitting with that. The clinical effect is not in doubt; the explanation is. That is an ordinary state of affairs in pharmacology and it is a good corrective to the confident mechanistic stories that circulate here.

Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.

The mental model, in four steps, that makes the rest of this site legible.

One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.

From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.

Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.

1,732 up / 422 down80% upvoted41 commentsid u1ih6820 Jun 2025

41 comments

18 in this archive, depth 5

best — the order this archive was captured in

u/zeynep_villalobos117 points·1 year ago

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

replysharereportpermalink
u/santiago_rasmussenOP138 points·1 year ago

Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.

replysharereportpermalink
u/niels_roos31 points·1 year ago

Yes. The central component is the one that explains the reports on this site better than gastric emptying does.

replysharereportpermalink
u/wholesome_lurker36 points·1 year ago

Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.

replysharereportpermalink
u/rina_bergstrom9 points·1 year ago

Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.

replysharereportpermalink
u/plain_titration11 points·1 year ago

This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.

replysharereportpermalink
u/vomit_free_since69 points·1 year ago·edited

Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.

replysharereportpermalink
u/emeka_chowdhury44 points·1 year ago

Same view. Tolerance developing to the gastric effect while the appetite effect persists explains most of what the side-effect board reports.

replysharereportpermalink
u/rafael_ostergaard40 points·1 year ago

Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.

replysharereportpermalink
u/nora_lundgren11 points·1 year ago

Is there any human data on that mechanism yet?

replysharereportpermalink
u/santiago_rasmussenOP-6 points·1 year ago

Is that from a human study or a preclinical model?

replysharereportpermalink
u/viktor_girard1 point·1 year ago

Do you have the paper, or a summary of it?

replysharereportpermalink
u/elodie_grimaldi-7 points·1 year ago

The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.

replysharereportpermalink
u/trialwatch_theotrial nerd10 points·1 year ago

Why mechanism talk keeps misleading people, including me.

A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.

The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.

replysharereportpermalink
u/santiago_rasmussenOP6 points·1 year ago

gastric emptying slows, it does not stop

replysharereportpermalink
u/enzo_danquah3 points·1 year ago

the central appetite effect is doing more work than the gut effect

replysharereportpermalink
u/kian_balogun4 points·1 year ago

preclinical is not clinical and rodents are not small people

replysharereportpermalink
u/gastric_emptying_g2 points·1 year ago·edited

preclinical is not clinical and rodents are not small people

Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.